Jon Dempsey is an expert in the discovery and development of biopharmaceuticals, specifically monoclonal antibodies, and in manufacturing and technology transfer of cell based processes. He has spent nearly 30 years working with biological molecules expressed in living organisms. He holds a PhD in Industrial Biotechnology from the University of Edinburgh where he studied the impact of industrial environments on antibody secreting cells.
Jon worked at Celltech (now Lonza Biologics) where he was part of the team which commercialised the first gene-activated biopharmaceutical and transferred this to manufacturing. He also designed novel processes for expressing proteins and again took these to manufacturing.
In 1998, he was one of the founding members of the Development team at Cambridge Antibody Technology, building the Upstream Process Team. Cambridge Antibody Technology was the inventor of in vitro human antibody libraries and with this company he took over ten molecules from this library into the clinic.
Having spent almost ten years at Cambridge Antibody Technology Jon joined Invitrogen to form a group commoditising technologies applicable to therapeutic protein development. They developed the world’s first commercially available cell line development kit and built complete workflows for early stage customers. He was the technical and commercial face of Invitrogen’s industrial business in the EU and India converting over twenty European and Indian companies to use their technology to develop therapies.
Jon has experience in transfering antibody processes globally, supporting products from discovery to the clinic. His teams have designed, commissioned and built development laboratories, setup pilot manufacturing facilities, and developed the expression technology still used today.
Jon is also the Managing Director of Dempsey Consulting and a founding Partner of Pathway Biopharma.